Search Within

Meghan Caitlin Thompson

Formats
  1. Meeting Abstract (27)
  2. Journal Article (10)
  3. Research Letter (8)
  4. Review (8)
  5. Editorial (2)
  6. Guidelines (1)
Groups
  1. GME, Medicine (56)
  2. Graduate Medical Education (56)
  3. Hematology-Oncology Fellows (56)
  4. Department of Medicine (45)
  5. Hematologic Malignancies, Division of (45)
  6. Adult Leukemia (39)

More Groups

People
  1. Lindsey Roeker (37)
  2. Anthony Mato (30)
  3. Andrew Zelenetz (17)
  4. Mark Geyer (10)
  5. Maria Palomba (9)
  6. Omar Abdel-Wahab (9)

More People

Years
  1. 2025 (8)
  2. 2024 (12)
  3. 2023 (10)
  4. 2022 (9)
  5. 2021 (12)
  6. 2020 (5)
Publications
  1. Blood (25)
  2. American Journal of Hematology (3)
  3. Blood Advances (3)
  4. British Journal of Haematology (3)
  5. Haematologica (3)
  6. Clinical Cancer Research (2)

More Publications

Publishers
  1. American Society of Hematology (29)
  2. John Wiley & Sons (4)
  3. Nature Publishing Group (4)
  4. Ferrata Storti Foundation (3)
  5. Wiley Blackwell (3)
  6. American Association for Cancer Research (2)

More Publishers

Results (56)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes of chronic lymphocytic leukemia and Richter Transformation following discontinuation of noncovalent Bruton's Tyrosine Kinase inhibitors
    Meeting Abstract

    Thompson, M. C.; Coombs, C. C.; Roeker, L. E.; Pagel, J. M.; Jensen, J. L.; Battiato, K. E.; Fox, Y.; Meyer, K.; Bailey, N.; Rhodes, J. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Addressing a new challenge in chronic lymphocytic leukemia: Outcomes of therapies after exposure to both a covalent Bruton's Tyrosine Kinase Inhibitor and venetoclax
    Meeting Abstract

    Thompson, M. C.; Roeker, L. E.; Coombs, C. C.; Jensen, J. L.; Kamdar, M.; Skarbnik, A.; Pagel, J. M.; Bailey, N.; Pu, J. J.; Jacobs, R.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A phase 2 study evaluating the addition of ublituximab and umbralisib (U2) to ibrutinib in patients with chronic lymphocytic leukemia (CLL): A minimal residual disease(MRD)-driven, time-limited approach
    Meeting Abstract

    Roeker, L. E.; Leslie, L. A.; Soumerai, J. D.; Falco, V.; Panton, G.; Zelenetz, A. D.; Falchi, L.; Park, J. H.; Pena-Velasquez, C.; Lebowitz, S.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Radiation therapy for patients with diffuse large B cell Richter's syndrome of CLL
    Meeting Abstract

    Sacchi De Camargo Correia, G.; Imber, B. S.; Hajj, C.; Thompson, M. C.; Mato, A. R.; Yahalom, J.; Roeker, L. E.
    Blood (2021)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: A multicentre, single-arm, phase 2 trial
    Journal Article

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V. E.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Hamilton, A. M.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • COVID-19 in patients with CLL: Improved survival outcomes and update on management strategies
    Research Letter

    Roeker, L. E.; Eyre, T. A.; Thompson, M. C.; Lamanna, N.; Coltoff, A. R.; Davids, M. S.; Baker, P. O.; Leslie, L.; Rogers, K. A.; Allan, J. N.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia
    Research Letter

    Roeker, L. E.; Knorr, D. A.; Thompson, M. C.; Nivar, M.; Lebowitz, S.; Peters, N.; Deonarine, I. Jr; Momotaj, S.; Sharan, S.; Chanlatte, V.; more...
    Leukemia (2021)

    Fulltext@MSK | Save
  • All in the family: Back-to-back kinase inhibitors for the treatment of chronic lymphocytic leukemia
    Editorial

    Thompson, M. C.; Roeker, L. E.; Mato, A. R.
    Haematologica (2021)

    Fulltext@MSK | Save
  • Searching for a home: Phosphoinositide 3-kinase inhibitors for chronic lymphocytic leukaemia in modern clinical practice
    Editorial

    Roeker, L. E.; Thompson, M. C.; Mato, A. R.
    British Journal of Haematology (2021)

    Fulltext@MSK | Save
  • Pirtobrutinib (LOXO‐305), a next generation highly selective non‐covalent BTK inhibitor in previously treated richter transformation: Results from the phase 1/2 bruin study
    Meeting Abstract

    Jurczak, W.; Shah, N. N.; Lamanna, N.; Eyre, T. A.; Woyach, J.; Lech‐Maranda, E.; Wierda, W. G.; Lewis, D.; Thompson, M. C.; Wang, D.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save